Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
NPM1-ALK ALK I1171T Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK Crizotinib anaplastic large cell lymphoma sensitive detail...
NPM1-ALK amp Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK amp Ceritinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK amp Alectinib anaplastic large cell lymphoma decreased response detail...
NPM1-ALK Alectinib anaplastic large cell lymphoma sensitive detail...
NPM1-ALK ASP3026 anaplastic large cell lymphoma sensitive detail...
NPM1-ALK Ceritinib anaplastic large cell lymphoma sensitive detail...
NPM1-ALK amp ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK amp Brigatinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK Brigatinib anaplastic large cell lymphoma sensitive detail...
NPM1-ALK ALK F1174V ALK L1198F Brigatinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK L1122V ALK L1196M Brigatinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK S1206C Brigatinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK I1171S Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK R1192P Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK G1269A Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK F1174L Ceritinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK T1151M Ceritinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK F1174I ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK C1156Y ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK I1171T ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK I1171N ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK G1128S ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK C1156F ALK D1203N ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK E1210K ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK C1156F ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK N1178H ASP3026 anaplastic large cell lymphoma resistant detail...
NPM1-ALK ALK L1196Q ASP3026 anaplastic large cell lymphoma sensitive detail...
NPM1-ALK ALK L1196Q Crizotinib anaplastic large cell lymphoma resistant detail...
NPM1-ALK Entrectinib anaplastic large cell lymphoma sensitive detail...
ALK fusion Crizotinib anaplastic large cell lymphoma sensitive detail...
Unknown unknown Brentuximab vedotin anaplastic large cell lymphoma not applicable detail...
NPM1-ALK CEP-28122 anaplastic large cell lymphoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Recruiting
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated
NCT00939770 Phase Ib/II Crizotinib Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
NCT01449461 Phase Ib/II Brigatinib A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113 Active, not recruiting
NCT01606878 Phase I Dexamethasone + Doxorubicin + Vincristine Cyclophosphamide + Topotecan Crizotinib Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Completed
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed
NCT01979536 Phase II Crizotinib Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Suspended
NCT02232516 Phase II Lenalidomide + Romidepsin Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Recruiting
NCT02420795 Phase Ib/II ONC201 Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Recruiting
NCT02464228 Phase II Tipifarnib Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma Recruiting
NCT02568267 Phase II Entrectinib Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (STARTRK-2) Recruiting
NCT02572453 Phase II Onalespib AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma Recruiting
NCT02616965 Phase I Brentuximab vedotin + Romidepsin A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma Recruiting
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep Recruiting
NCT02729961 Phase Ib/II Brentuximab vedotin + Ceritinib Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Recruiting
NCT02978625 Phase II Nivolumab + Talimogene laherparepvec Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting
NCT03017820 Phase I VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Suspended
NCT03075553 Phase II Nivolumab Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting
NCT03372057 Phase II Duvelisib A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) Recruiting
NCT03586999 Phase Ib/II Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Recruiting
NCT03719898 Phase II Brigatinib Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Recruiting
NCT03905135 Phase I Avelumab + rhIL-15 Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies Not yet recruiting